RxDoctor Payments Data

Julie Chang, MD

Hematology · Madison, WINPI 1679524078

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,315 of the $17,081 with a category attached, or 83.8%. It is spread thinly across 10 manufacturers, the largest accounting for just 20.9%.

$17,081in general payments, 2019–2025

Across 19 payments — averaging $898.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$4K
  • Incyte Corporation$3K
  • F. Hoffmann-la Roche AG$2K
  • Beigene, Ltd.$2K
  • Beigene USA, Inc.$2K
  • plus $2K from 4 others
$520,486in research payments, 2019–2025

Across 53 payments — averaging $9820.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$165K
  • Janssen Research & Development, LLC$120K
  • TG Therapeutics, Inc.$102K
  • Eli Lilly$51K
  • Bristol Myers Squibb$47K
  • Adaptive Biotechnologies Corporation$29K
  • plus $5K from 2 others

What the payments were for

  • Consulting fees$14,31584%
  • Speaking & faculty fees$2,62415%
  • Food & beverage$1201%
  • Education$220%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,511
Medicare patients
186
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib62$890,922
VenclextaVenetoclax44$626,069
JaypircaPirtobrutinib25$452,622
CalquenceAcalabrutinib Maleate25$359,103
ImbruvicaIbrutinib18$269,991
Acyclovir318$3,776
Fluconazole33$2,069
Ondansetron Hcl37$650
Dexamethasone14$559
Famotidine49$419
Prochlorperazine Maleate29$397
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim90$388
Omeprazole42$313
Potassium Chloride19$306
Olanzapine13$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$1,650$890,92262 claims
AbbVieVenclexta$3,575$626,06944 claims
AstraZenecaCalquence$3,569$359,10325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other hematology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →